Variability and reproducibility of flow-mediated dilatation in amulticentre clinical trial

European Heart Journal

Volumn 34, Issue 45, 2013, Pages 3501-3507

  Charakida, Marietta ^a   De Groot, Eric ^b   Loukogeorgakis, Stavros P ^a   Khan, Tauseef ^a   Lü scher, Thomas ^c   Kastelein, John J ^b   Gasser, Theo ^c   Deanfield, John E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Coronary artery disease; FMD; Power curve; Reproducibility

Indexed keywords

DALCETRAPIB; PLACEBO;

ADULT; ARTICLE; ATHEROSCLEROSIS; B SCAN; CONTROLLED STUDY; FEMALE; FLOW MEDIATED DILATATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; VASODILATATION;

CORONARY ARTERY DISEASE; FMD; POWER CURVE; REPRODUCIBILITY;

BLOOD FLOW VELOCITY; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; VASODILATION;

EID: 84890537763     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht223     Document Type: Article

References (25)

1. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van HL, Tracy RP, Lloyd-Jones DM. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366:321-329.
2. Charakida M, Masi S, Loukogeorgakis SP, Deanfield JE. The role of flow-mediated dilatation in the evaluation and development of antiatherosclerotic drugs. Curr Opin Lipidol 2009;20:460-466.
3. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, KiowskiW, Luscher TF, Mancia G, Natali A, Oliver JJ, PessinaAC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S,Webb DJ. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:233-246.
4. Hadi HA, Carr CS, Al SJ. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005;1:183-198.
5. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the 'vulnerable' patient. Circulation 2004;110:1926-1932.
6. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: A meta-Analysis. Int J Cardiovasc Imaging 2010;26:631-640.
7. Charakida M, Masi S, Luscher TF, Kastelein JJ, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J 2010;31:2854-61.
8. Donald AE, Halcox JP, Charakida M, Storry C, Wallace SM, Cole TJ, Friberg P, Deanfield JE. Methodological approaches to optimize reproducibility and power in clinical studies of flow-mediated dilation. J Am Coll Cardiol 2008;51:1959-1964.
9. Donald AE, Charakida M, Falaschetti E, Lawlor DA, Halcox JP, Golding J, Hingorani AD, Smith GD, Deanfield JE. Determinants of vascular phenotype in a large childhood population: the Avon Longitudinal Study of Parents and Children (ALSPAC). Eur Heart J 2010;31:1502-10.
10. Kastelein JJ, Duivenvoorden R, Deanfield J, De GE, Jukema JW, Kaski JC, Munzel T, Taddei S, Lehnert V, Burgess T, Kallend D, Luscher TF. Rationale and design of dal-VESSEL: A study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Curr Med Res Opin 2011;27: 141-150.
11. Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Munzel T, Kastelein JJ, Deanfield JE. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012;33: 857-865.
12. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D,Charbonneau F, CreagerMA, Deanfield J,Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265.
13. Donald AE, Charakida M, Cole TJ, Friberg P, Chowienczyk PJ, Millasseau SC, Deanfield JE, Halcox JP. Non-invasive assessment of endothelial function: which technique? J Am Coll Cardiol 2006;48:1846-1850.
14. NeunteuflT, Heher S, Katzenschlager R,Wolfl G, Kostner K, Maurer G,Weidinger F. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000;86:207-210.
15. Schachinger V, Zeiher AM. Prognostic implications of endothelial dysfunction: does it mean anything? Coron Artery Dis 2001;12:435-443.
16. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007;115:2390-2397.
17. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115.
18. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE. Non-invasive measurement of human endothelium dependent arterial responses: Accuracy and reproducibility. Br Heart J 1995;74: 247-253.
19. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26:1235-1241.
20. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: A statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:7-17.
21. Woodman RJ, Playford DA,Watts GF, Cheetham C, Reed C, Taylor RR, Puddey IB, Beilin LJ, Burke V, Mori TA, Green D. Improved analysis of brachial artery ultrasound using a novel edge-detection software system. J Appl Physiol 2001;91:929-937.
22. Ghiadoni L, Faita F, Salvetti M, Cordiano C, Biggi A, Puato M, Di MA, De SL, Volpe M, Ambrosio G, Gemignani V, Muiesan ML, Taddei S, Lanza GA, Cosentino F. Assessment of flow-mediated dilation reproducibility: A nationwide multicenter study. J Hypertens 2012;30:1399-1405.
23. Anderson TJ, Charbonneau F, Title LM, Buithieu J, Rose MS, Conradson H, Hildebrand K, Fung M, VermaS, Lonn EM. Microvascular function predicts cardiovascular events in primary prevention: long-Term results from the Firefighters and Their Endothelium (FATE) study. Circulation 2011;123:163-169.
24. Pyke KE, Tschakovsky ME. The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J Physiol 2005; 568(Pt 2):357-369.
25. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky ME, Green DJ. Assessment of flow-mediated dilation in humans: A methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011;300:H2-H12.